Cold-Chain IQ’s Pharma Sea Freight Working Group
This working group brings together the key stakeholders to drive unification and best practice in temperature controlled sea freight for pharmaceuticals.
In London 2017, the Ocean Freight Working Group will be presenting their updated best practice guide for transporting pharma products at sea. With input from the newly created Technology Subgroup, the insight that will be shared in 2017 will help you develop internal guidelines for your pharma sea freight
Bringing together leading manufacturers such as Pfizer, AstraZeneca, Novartis and GSK alongside freight forwarders and shipping lines the group will meet in September in London to align priorities and drive unification in a currently mismatched industry.
Pharma is continuously looking at alternatives to air freight and sea is a cost effective option, but there are misconceptions around the liability, the quality control and handling of the reefers as well as the understanding of each and every key role.
This group, formed in May 2015 aims to understand and define the key stakeholders in the reefer supply chain.
Understand who all the stakeholders are in the “reefer” supply chain
Define each of their roles and responsibilities
Draw up a “best practice” guide to sea freight using reefers
Understand the liability issues and agree a way of working with the shipping lines
Longer term look to issuing forwarders, shipping lines and port operators with a charter mark to signify compliance with best practice.
The updated report will be published in late 2016, with the latest meeting developments and findings, and the group will be presenting their findings at the Temperature Controlled Logistics
in London 2017
AstraZeneca, GSK, Pfizer, Novartis, Maersk, Agility, Softbox, Kuehne Nagel and DP World